Lundbeck CEO puts 6M crowns into company stock; Pfizer to sell off 4 products for Hospira deal nod;

@FiercePharma: ICYMI Friday: Novartis shells out up to $1B to test GSK's Arzerra in MS. Item | Follow @FiercePharma

@EricPFierce: Email exchange with Merck CEO posted by union shows frustrations over job cuts, double shifts. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Novartis places $1B bet to push CLL med Arzerra into MS fray. FiercePharmaMarketing story | Follow @CarlyHFierce

> Lundbeck CEO Kåre Schultz, in a vote of confidence in his recently announced restructuring plans for the company, ploughed almost 6 million Danish crowns, or about $904,000, into Lundbeck shares. Report

> Pfizer ($PFE) won U.S. approval for its big Hospira ($HSP) buyout, provided it sells off four sterile injectable drugs; the company has already promised to divest some drug rights to win EU approval. Report

> The European Commission gave the green light to Perrigo's ($PRGO) proposed deal to buy a range of products from GlaxoSmithKline ($GSK). Report

> Partnerships with Big Pharma firms are helping to drive growth at Korea's drugmakers, including Hanmi Pharmaceuticals, which recently inked a licensing deal with Boehringer Ingelheim. Report

> Merck KGaA plans to shut down Bangalore GeNei, an Indian company it bought in 2009. Report

> India's Glenmark Pharmaceuticals rolled out a new diabetes drug to compete with Big Pharma's DPP-4 meds. Report

Medical Device News

@FierceMedDev: DARPA-backed Wyss Institute sepsis device being readied for human trials. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Edge files for up to $115M IPO to support locally delivered med for brain aneurysms. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Olympus duodenoscopes linked to suspected superbug outbreak at California hospital. More | Follow @EmilyWFierce

> Bayer's Grants4Apps accelerator funds its second crop of digital health startups. Story

> Micro-cap TriVascular starts post-market registry trial as it raises $10M. Article

Biotech News

@FierceBiotech: ICYMI Friday: Takeda rolls toward EU approval with its heir to Velcade. Story | Follow @FierceBiotech

@JohnCFierce: AstraZeneca lures Bohen from Genentech to fill R&D post vacated by Morrison. Report | Follow @JohnCFierce

> BTD in hand, Exelixis speeds cabo application to FDA. More

> Vital Therapies' shares crash on news of a PhIII failure. Story

> Hatteras rounds up $90M to lead a biotech rebound in NC. Article

Animal Health News

> Report: Dietary supplements gaining popularity as aging dogs fight arthritis. Report

> Free of Zoetis, Sweden's Oasmia hits the road to pitch IPO. Article

> USDA solicits bids for bird flu vaccine production plan. Item

> Beef producers lash out at USDA's choice of Humane Society vet for advisory panel. Story

> Petco files for IPO, emphasizing focus on animal health. News

Biotech IT News

> Biogen taps ice bucket cash to build ALS database. More

> Life science unit graduates from Google X to become standalone business. News

> Intel makes pitch to become a hub for cancer data sharing. Report

> Flatiron teams with Guardant to mine blood test data for cancer R&D. Story

> Illumina teams with VCs to place $100M bet on consumer genomics. Article

Pharma Marketing News

> Janssen's new Prezcobix push urges HIV patients to share pics with their docs. Story

> Novartis places $1B bet to push CLL med Arzerra into MS fray. Report

> Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal. Item

> Sure, there's an app for that, but few top pharma apps get most of the attention. More

> Purdue hones abuse-deterrent edge with painkiller safety campaign. Article

And Finally... Major U.S. corporations are saving up to $3 trillion by shifting their retirees to private Obamacare exchanges. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.